Filing Flows › Comparisons › QURE vs AVBP
uniQure N.V. vs ArriVent BioPharma: QURE and AVBP compared
uniQure N.V. is the larger company: $5.2M of revenue in its latest quarter (Q3 2026) against $5.0M for ArriVent BioPharma (Q3 2026).
Where the money goes: QURE and AVBP
uniQure N.V. (QURE) · Q3 2026
uniQure N.V., Q3 2026: revenue $5.2M (+40% year over year), net loss $61.2M, operating cash flow −$47.8M. The chart follows the revenue to costs, profit and cash.
ArriVent BioPharma (AVBP) · Q3 2026
ArriVent BioPharma, Q3 2026: revenue $5.0M, operating margin -867.5%, net loss $40.3M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| uniQure N.V. (QURE) | ArriVent BioPharma (AVBP) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $5.2M | $5.0M |
| Revenue growth, Y/Y | +40% | — |
| Operating margin | n/m | -867.5% |
| Net earnings | −$61.2M | −$40.3M |
| Net margin | — | -806.3% |
| Operating cash flow | −$47.8M | −$40.7M |
Questions
Which is bigger, uniQure N.V. or ArriVent BioPharma?
uniQure N.V. is the larger company: $5.2M of revenue in its latest quarter (Q3 2026) against $5.0M for ArriVent BioPharma (Q3 2026).
More: uniQure N.V. earnings · how uniQure N.V. makes money · ArriVent BioPharma earnings · how ArriVent BioPharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.